Who are Oxervate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rozlytrek, Vitrakvi, Oxervate, Oxervate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cenegermin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Oxervate — Competitive Intelligence Brief

Oxervate (CENEGERMIN) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant Human Nerve Growth Factor [EPC]. Area: Neuroscience.

marketed Recombinant Human Nerve Growth Factor [EPC] High affinity nerve growth factor receptor Neuroscience Recombinant protein Live · refreshed every 30 min

Target snapshot

Oxervate (CENEGERMIN) — Dompe farmaceutici s.p.a.. Oxervate works by binding to the high affinity nerve growth factor receptor to stimulate nerve growth and repair.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oxervate TARGET	CENEGERMIN	Dompe farmaceutici s.p.a.	marketed	Recombinant Human Nerve Growth Factor [EPC]	High affinity nerve growth factor receptor	2017-01-01
Rozlytrek	entrectinib	Roche	marketed		High affinity nerve growth factor receptor	2019-01-01
Vitrakvi	LAROTRECTINIB	Bayer	marketed	Kinase Inhibitor [EPC]	High affinity nerve growth factor receptor	2018-01-01
Oxervate	Cenegermin-Bkbj	Dompe farmaceutici s.p.a.	marketed	Recombinant Human Nerve Growth Factor [EPC]	High affinity nerve growth factor receptor
Oxervate	Oxervate	Dompé Farmaceutici S.p.A	marketed		High affinity nerve growth factor receptor, Tumor necrosis factor receptor superfamily member 16

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant Human Nerve Growth Factor [EPC] class)

Dompe farmaceutici s.p.a. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxervate — Competitive Intelligence Brief. https://druglandscape.com/ci/cenegermin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab